Attached files
| file | filename |
|---|---|
| S-1 - FORM S-1 - Adhera Therapeutics, Inc. | ds1.htm |
| EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - Adhera Therapeutics, Inc. | dex211.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Marina Biotech, Inc.:
We consent to the use of our report with respect to the consolidated financial statements of Marina Biotech, Inc. incorporated by reference herein and to the reference to our firm under the heading “Experts” in the prospectus.
Our report dated March 23, 2011 contains an explanatory paragraph that states that the Company has incurred recurring losses and has an accumulated deficit, and has had recurring negative cash flows from operations, that raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.
/s/ KPMG LLP
Seattle, Washington
March 25, 2011